Today: Nov 17, 2024

The Endpoints Slack interview: How Beam CEO John Evans thinks about the science and business of genetic editing

The Endpoints Slack interview: How Beam CEO John Evans thinks about the science and business of genetic editing
February 5, 2024



Even though there were groundbreaking approvals for genetic medicines in sickle cell disease last year, John Evans believes that his start-up can continue to make advancements in the field. Beam Therapeutics began 2024 by announcing that it had administered its base-editing program to the first sickle cell patient, with initial human results expected in the second half of 2024. Endpoints News had the opportunity to discuss Beam’s sickle cell plans amid growing competition, as well as the potential evolution of CRISPR over the next two decades, with Evans, who has been leading Beam since 2017 and was previously an executive at Agios Pharmaceuticals, in a private Slack channel conversation.

OpenAI
Author: OpenAI

Don't Miss

Eating place executives cannot look ahead to 2025 after sluggish site visitors and wave of bankruptcies

Eating place executives cannot look ahead to 2025 after sluggish site visitors and wave of bankruptcies

A McDonald’s eating place in El Sobrante, California, on Oct. 23, 2024.David
‘The Interview’ Podcast: Ellen Wiebe

‘The Interview’ Podcast: Ellen Wiebe

Previous this 12 months, my mom ended her existence by the use